XenoPort Gives Up On Reflux Drug After It Fails To Beat Placebo
Negative results thwart a potential partnership strategy surrounding arbaclofen placerbil, which still holds potential in spasticity.
Negative results thwart a potential partnership strategy surrounding arbaclofen placerbil, which still holds potential in spasticity.